Literature DB >> 16773326

[Positive screening for MRSA--clinical consequences?].

M Neumaier1, I Kappstein, M A Scherer.   

Abstract

BACKGROUND: The worldwide rise of MRSA is equivalent to an increase of nasal colonization with MRSA. The objectives of this study were to investigate the rate of occult nasal MRSA colonization in trauma patients, to elucidate the role of MRSA carriers for endogenous infection (nose --> wound) and to check the efficiency of mupirocin therapy. PATIENTS AND METHODS: A total of 643 consecutive trauma patients underwent MRSA screening (nasal swabs) on admission. At the same time all MRSA wound infections were registered and all isolates were analysed with PFGE (pulsed-field gel electrophoresis) to detect cross-infection between individuals.
RESULTS: In 13 patients (2.0%) we found MRSA in the nose and limited isolation as well as therapy with mupirocin were performed. No endogenous transmission of MRSA from the nose to the wound could be seen, and no cross-infection to other patients could be detected.
CONCLUSION: Our findings suggest that in our patients with nasal colonization the risk of intra- and interindividual transmission of MRSA is very small. Therefore, in trauma patients screening on admission does not seem to be absolutely necessary either for clinical or for epidemiological reasons.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16773326     DOI: 10.1007/s00113-006-1103-8

Source DB:  PubMed          Journal:  Unfallchirurg        ISSN: 0177-5537            Impact factor:   1.000


  27 in total

1.  A Dutch approach to methicillin-resistant Staphylococcus aureus.

Authors:  J Verhoef; D Beaujean; H Blok; A Baars; A Meyler; C van der Werken; A Weersink
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1999-07       Impact factor: 3.267

2.  Molecular epidemiology of methicillin-resistant Staphylococcus aureus in Finland.

Authors:  S Salmenlinna; O Lyytikäinen; P Kotilainen; R Scotford; E Siren; J Vuopio-Varkila
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-02       Impact factor: 3.267

3.  Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization.

Authors:  Susan S Huang; Richard Platt
Journal:  Clin Infect Dis       Date:  2003-01-17       Impact factor: 9.079

Review 4.  Control of endemic MRSA-what is the evidence? A personal view.

Authors:  C Marshall; S Wesselingh; M McDonald; D Spelman
Journal:  J Hosp Infect       Date:  2004-04       Impact factor: 3.926

5.  Efficient detection and long-term persistence of the carriage of methicillin-resistant Staphylococcus aureus.

Authors:  M D Sanford; A F Widmer; M J Bale; R N Jones; R P Wenzel
Journal:  Clin Infect Dis       Date:  1994-12       Impact factor: 9.079

6.  Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus.

Authors:  S Harbarth; S Dharan; N Liassine; P Herrault; R Auckenthaler; D Pittet
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

7.  The epidemiology of mupirocin resistance among methicillin-resistant Staphylococcus aureus at a Veterans' Affairs hospital.

Authors:  J E Vasquez; E S Walker; B W Franzus; B K Overbay; D R Reagan; F A Sarubbi
Journal:  Infect Control Hosp Epidemiol       Date:  2000-07       Impact factor: 3.254

8.  Risk factors for nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus.

Authors:  M Pujol; C Peña; R Pallares; J Ayats; J Ariza; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-01       Impact factor: 3.267

9.  Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991.

Authors:  A L Panlilio; D H Culver; R P Gaynes; S Banerjee; T S Henderson; J S Tolson; W J Martone
Journal:  Infect Control Hosp Epidemiol       Date:  1992-10       Impact factor: 3.254

Review 10.  The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection.

Authors:  R P Wenzel; T M Perl
Journal:  J Hosp Infect       Date:  1995-09       Impact factor: 3.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.